An interventional study of PAL2 and CINEMA in Coronary Heart Disease, sponsored by University Hospitals Cleveland Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.
Among the 274 studies in Coronary Disease with a site in United States, this one is the 57th largest by planned enrollment of the 184 interventional ones that give a count, is one of 2 that started in 2022, is one of 78 with no phase, reaches primary completion later than 7 of the 22 other live ones, and was the 259th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
West Virginia School of Osteopathic Medicine · Sites in United States
Ages 18–64
University of California, Los Angeles · Sites in United States
Ages 60–80
Weill Medical College of Cornell University · Sites in United States, Austria, Canada and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
274 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 43 · Phase 3 36 · Phase 4 18
First in 1973; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 200 across the 184 interventional studies, 324 across the 87 observational. Of the 235 that completed or were terminated, 88 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 274 have an industry lead sponsor. The 10 most frequent:
University Hospitals Cleveland Medical Center is the lead sponsor of 296 studies on the registry; 46 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 30 (83%) have results posted.
University Hospitals Cleveland Medical Center has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
| NCT06170541Johns Hopkins UniversityCORE-COMPARE Pilot Study | 2026-12 |
| NCT05918380University Hospitals Cleveland Medical CenterProject 3: ACHIEVE- CHD | 2027-01-01 |
| NCT00406185Intermountain Health Care, Inc.Database Registry of the Intermountain Heart Collaborative Study | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 274 studies in Coronary Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Project 2) and coronary heart disease (CHD, Project 3), which drive downstream lifespan inequality. All three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. All three projects will also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 3 of the ACHIEVE GREATER Center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have at least two of the following risk factors identified at a UH health fair screenings, with one risk factor being with SBP, A1c, or LDL:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PAL2
Behavioral: PAL2
Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA)
Other: CINEMA
Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2. PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education.
Also known as: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
Triple Goal
Percent reaching triple goal of BP \<130/80 mm Hg, HbA1c\<5.7% and LDL-C \<130 mg/dl (\<100 if high-risk)
Time frame: 12 months
Change in HbA1c as measured by blood work
Percent change in HbA1c
Time frame: baseline, 12 months
Change in LDL-C as measured by blood work
Percent change in LDL-C
Time frame: baseline, 12 months
Change in blood pressure
Percent change in blood pressure
Time frame: baseline, 12 months
Change in weight
Percent change in weight
Time frame: baseline, 12 months
Health Visits and Lifestyle Changes - Medical/Mental Health Visits
1-year rate of new medical/mental health visits
Time frame: 12 months after cessation of intervention or 24 months after enrollment
Health Visits and Lifestyle Changes - Smoking Cessation
1-year rate of smoking cessation
Time frame: 12 months after cessation of intervention or 24 months after enrollment
Health Visits and Lifestyle Changes - Diet
1-year rate of changes in diet
Time frame: 12 months after cessation of intervention or 24 months after enrollment
Health Visits and Lifestyle Changes - Activity
1-year rate of changes in activity
Time frame: 12 months after cessation of intervention or 24 months after enrollment
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 52 months is above that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospitals Cleveland Medical Center →